Detergent enhances binding of a secreted HLA-A2 molecule to solid phase peptides. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Detergent enhances binding of a secreted HLA-A2 molecule to solid phase peptides.

Hum Immunol. 1991 Nov;32(3):183-93. Unique Identifier : AIDSLINE MED/92129228
Tussey LG; Frelinger JA; Department of Microbiology and Immunology, University of North; Carolina, Chapel Hill 27599-7290.


Abstract: We have constructed a secreted analogue (sA2) of the human class I molecule HLA-A2. sA2 was affinity purified both in the presence and absence of detergent and the effects of detergent on the magnitude and specificity of A2 binding to solid phase peptides tested. sA2 purified in the presence of detergent and detergent-solubilized A2 are shown to function comparably in the binding of the synthetic peptide M.Y + 57-68, a known T-cell epitope derived from the influenza A matrix protein. The molecules binding to M.Y + 57-68 typically represent 8% to 10% of the added protein. In contrast, less than 1% of sA2 protein purified in the absence of detergent binds M.Y + 57-68. This reduced binding is not due to a change in the affinity of sA2 for M.Y + 57-68. Addition of detergent at various stages of the purification and iodination procedures indicates that the longer the sA2 molecules are exposed to detergent the better they bind. However, the concentration of detergent during the actual binding assay does not appear to be critical. We also find that while the sA2-detergent and the sA2-no detergent molecules differ in the extent to which they bind various peptides, they do not differ in their patterns of binding. We conclude that detergent probably does not influence the specificity of class I/peptide binding but does increase the number of sA2 molecules that can participate in the binding of peptide either by generating and stabilizing empty sA2 molecules or by stabilizing a structure that is more amenable to binding peptide.
Keywords: Amino Acid Sequence Base Sequence Cell Line *Detergents Electrophoresis, Polyacrylamide Gel Enzyme-Linked Immunosorbent Assay Gene Expression Human HIV Antigens/CHEMISTRY HLA-A2 Antigen/*CHEMISTRY/GENETICS Molecular Sequence Data Orthomyxovirus Type A, Human/*CHEMISTRY Peptides/CHEMISTRY Polymerase Chain Reaction Secretory Component/*CHEMISTRY/GENETICS Support, U.S. Gov't, P.H.S. Transfection Viral Matrix Proteins/*CHEMISTRY JOURNAL ARTICLE

KWDaminoacidsequencebasesequencecelllineKWDdetergentselectrophoresis,polyacrylamidegelenzyme-linkedimmunosorbentassaygeneexpressionhumanhivantigens/chemistryhla-a2antigen/KWDchemistry/geneticsmolecularsequencedataorthomyxovirustypea,human/KWDchemistrypeptides/chemistrypolymerasechainreactionsecretorycomponent/KWDchemistry/geneticssupport,uKWDsKWDgov't,pKWDhKWDsKWDtransfectionviralmatrixproteins/KWDchemistryjournalarticle
920530
M9250911


Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .